WO2003031588A3 - Hepatitis c virus vaccine - Google Patents

Hepatitis c virus vaccine Download PDF

Info

Publication number
WO2003031588A3
WO2003031588A3 PCT/US2002/032512 US0232512W WO03031588A3 WO 2003031588 A3 WO2003031588 A3 WO 2003031588A3 US 0232512 W US0232512 W US 0232512W WO 03031588 A3 WO03031588 A3 WO 03031588A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
hepatitis
virus vaccine
ns5b
hcv
Prior art date
Application number
PCT/US2002/032512
Other languages
French (fr)
Other versions
WO2003031588A2 (en
Inventor
Emilio A Emini
David C Kaslow
Andrew J Bett
John W Shiver
Alfredo Nicosia
Armin Lahm
Alessandra Luzzago
Riccardo Cortese
Stefano Colloca
Original Assignee
Merck & Co Inc
Angeletti P Ist Richerche Bio
Emilio A Emini
David C Kaslow
Andrew J Bett
John W Shiver
Alfredo Nicosia
Armin Lahm
Alessandra Luzzago
Riccardo Cortese
Stefano Colloca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003534559A priority Critical patent/JP4475561B2/en
Priority to DE60236364T priority patent/DE60236364D1/en
Application filed by Merck & Co Inc, Angeletti P Ist Richerche Bio, Emilio A Emini, David C Kaslow, Andrew J Bett, John W Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca filed Critical Merck & Co Inc
Priority to AT02773740T priority patent/ATE467680T1/en
Priority to CN028246659A priority patent/CN1582337B/en
Priority to PCT/US2002/032512 priority patent/WO2003031588A2/en
Priority to US10/492,178 priority patent/US7598362B2/en
Priority to CA2718802A priority patent/CA2718802C/en
Priority to DK02773740.2T priority patent/DK1436397T3/en
Priority to CA2461380A priority patent/CA2461380C/en
Priority to EP02773740A priority patent/EP1436397B1/en
Priority to SI200230911T priority patent/SI1436397T1/en
Priority to AU2002337840A priority patent/AU2002337840B2/en
Publication of WO2003031588A2 publication Critical patent/WO2003031588A2/en
Publication of WO2003031588A3 publication Critical patent/WO2003031588A3/en
Priority to US12/396,747 priority patent/US8142794B2/en
Priority to US12/633,104 priority patent/US8530234B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
PCT/US2002/032512 2001-10-11 2002-10-10 Hepatitis c virus vaccine WO2003031588A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA2461380A CA2461380C (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine
DK02773740.2T DK1436397T3 (en) 2001-10-11 2002-10-10 Hepatitis C virus vaccine
AT02773740T ATE467680T1 (en) 2001-10-11 2002-10-10 HEPATITIS C VIRUS VACCINE
DE60236364T DE60236364D1 (en) 2001-10-11 2002-10-10 Hepatitis-c-virus-impfstoff
PCT/US2002/032512 WO2003031588A2 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine
US10/492,178 US7598362B2 (en) 2001-10-11 2002-10-10 Hepatitis C virus vaccine
EP02773740A EP1436397B1 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine
JP2003534559A JP4475561B2 (en) 2001-10-11 2002-10-10 Hepatitis C virus vaccine
CN028246659A CN1582337B (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine
CA2718802A CA2718802C (en) 2001-10-11 2002-10-10 Recombinant nucleic acids comprising regions of ad6
SI200230911T SI1436397T1 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine
AU2002337840A AU2002337840B2 (en) 2001-10-11 2002-10-10 Hepatitis C virus vaccine
US12/396,747 US8142794B2 (en) 2001-10-11 2009-03-03 Hepatitis C virus vaccine
US12/633,104 US8530234B2 (en) 2001-10-11 2009-12-08 Hepatitis C virus vaccine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32865501P 2001-10-11 2001-10-11
US60/328,655 2001-10-11
US36377402P 2002-03-13 2002-03-13
US60/363,774 2002-03-13
PCT/US2002/032512 WO2003031588A2 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10492178 A-371-Of-International 2002-10-10
US12/396,747 Division US8142794B2 (en) 2001-10-11 2009-03-03 Hepatitis C virus vaccine

Publications (2)

Publication Number Publication Date
WO2003031588A2 WO2003031588A2 (en) 2003-04-17
WO2003031588A3 true WO2003031588A3 (en) 2003-10-30

Family

ID=42828995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032512 WO2003031588A2 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine

Country Status (9)

Country Link
US (3) US7598362B2 (en)
EP (1) EP1436397B1 (en)
JP (1) JP4475561B2 (en)
CN (1) CN1582337B (en)
AT (1) ATE467680T1 (en)
AU (1) AU2002337840B2 (en)
CA (1) CA2461380C (en)
DK (1) DK1436397T3 (en)
WO (1) WO2003031588A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389206C (en) 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CA2419418A1 (en) 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
EP1436397B1 (en) * 2001-10-11 2010-05-12 Merck Sharp & Dohme Corp. Hepatitis c virus vaccine
PT1436397E (en) * 2001-10-11 2010-07-15 Angeletti P Ist Richerche Bio Hepatitis c virus vaccine
CA2585523A1 (en) * 2004-11-02 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof
WO2006086188A2 (en) * 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US7951531B2 (en) * 2005-02-17 2011-05-31 University Of Iowa Research Foundation Flavivirus NS5A proteins for the treatment of HIV
DE102005015005A1 (en) * 2005-04-01 2006-10-05 Qiagen Gmbh Process for treating a sample containing biomolecules
WO2007031867A2 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-stru tural ns3/4a fusion gene
US9056090B2 (en) 2005-06-17 2015-06-16 Msd Italia Srl Hepatitis C virus nucleic acid vaccine
CN1887350B (en) * 2005-06-28 2010-10-06 深圳市源兴生物医药科技有限公司 Recombinant vaccine and its use
JP5138601B2 (en) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド Recombinant virus stabilization formulation
KR20090079938A (en) * 2006-10-12 2009-07-22 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
AU2008251982A1 (en) 2007-01-24 2008-11-20 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus epidermidis
EP2233575A4 (en) * 2007-12-18 2012-12-26 Univ Peking Peoples Hospital An anti-hcv vaccine and preparation methods and uses thereof
EP2313503A4 (en) * 2008-08-01 2014-01-08 Merck Sharp & Dohme Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
KR101609233B1 (en) 2008-10-29 2016-04-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Improved HCV vaccines and methods for using the same
MX2011005579A (en) 2008-11-26 2011-06-30 Merck Sharp & Dohme Polypeptides for inducing a protective immune response against staphylococcus aureus.
EP2384201A4 (en) 2008-11-26 2013-01-09 Merck Sharp & Dohme Polypeptides for inducing a protective immune response against staphylococcus aureus
ES2898235T3 (en) 2009-02-02 2022-03-04 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid and amino acid sequences, vectors containing them, and their uses
CN102645534B (en) * 2012-04-26 2015-08-12 杭州市萧山区第一人民医院 Based on the method for quantum point coding microball chip detection hepatitis C virus
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
US20180000926A1 (en) * 2015-01-15 2018-01-04 Babita Agrawal Methods of inducing an immune response to hepatitis c virus
CN108277230A (en) * 2018-02-07 2018-07-13 华中科技大学 A kind of fusion dna and its vaccine of preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
WO2001030812A2 (en) * 1999-10-27 2001-05-03 Chiron Corporation Activation of hcv-specific t cells

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0464287A1 (en) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide
IT1270939B (en) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio PROCEDURE FOR THE PREPARATION OF IMMUNOGEN AND DIAGNOSTIC REAGENTS, AND IMMUNOGEN AND DIAGNOSTIC REAGENTS SO OBTAINABLE.
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
IT1272179B (en) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
CA2117668C (en) * 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
IT1278077B1 (en) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE ACTIVITIES OF RNA-DEPENDENT RNA POLYMERASE AND OF TERMINAL NUCLEOTIDYLTRANSPHERASE CODED BY THE
DE69638058D1 (en) 1995-06-15 2009-11-26 Crucell Holland Bv Packaging systems for human recombinant adenoviruses for gene therapy
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
WO1998043702A2 (en) 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
AU7553698A (en) 1997-05-12 1998-12-08 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
US6221646B1 (en) * 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
IL137458A0 (en) 1998-01-30 2001-07-24 Gen Hospital Corp Genetic immunization with nonstructural proteins of hepatitis c virus
JP2002511396A (en) 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド Needleless administration of polynucleotide preparations
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6156588A (en) 1998-06-23 2000-12-05 Vlsi Technology, Inc. Method of forming anti-fuse structure
WO2000011202A1 (en) 1998-08-24 2000-03-02 Genzyme Corporation Cationic complexes of polymer-modified adenovirus
IL144060A0 (en) 1999-01-14 2002-04-21 Novartis Ag Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
ATE376558T1 (en) 1999-11-24 2007-11-15 Novartis Vaccines & Diagnostic NEW NON-STRUCTURAL HCV POLYPEPTIDE
ES2319727T3 (en) 1999-12-01 2009-05-12 Novartis Vaccines And Diagnostics, Inc. STIMULATION OF SPECIFIC ANTIBODIES OF HCV.
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
AU9456201A (en) 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
EP1436397B1 (en) * 2001-10-11 2010-05-12 Merck Sharp & Dohme Corp. Hepatitis c virus vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
WO2001030812A2 (en) * 1999-10-27 2001-05-03 Chiron Corporation Activation of hcv-specific t cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Also Published As

Publication number Publication date
CA2461380A1 (en) 2003-04-17
AU2002337840B2 (en) 2007-08-09
EP1436397A2 (en) 2004-07-14
CN1582337A (en) 2005-02-16
CA2461380C (en) 2011-03-22
US20100129901A1 (en) 2010-05-27
EP1436397B1 (en) 2010-05-12
US20090233992A1 (en) 2009-09-17
US7598362B2 (en) 2009-10-06
US8142794B2 (en) 2012-03-27
JP2005505286A (en) 2005-02-24
JP4475561B2 (en) 2010-06-09
ATE467680T1 (en) 2010-05-15
US8530234B2 (en) 2013-09-10
DK1436397T3 (en) 2010-08-09
CN1582337B (en) 2011-12-14
WO2003031588A2 (en) 2003-04-17
EP1436397A4 (en) 2005-02-16
US20040247615A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2003031588A3 (en) Hepatitis c virus vaccine
Zhong et al. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase
Kunkel et al. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein
Tanaka et al. Structure of the 3'terminus of the hepatitis C virus genome
EP1256628A3 (en) Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
Zhong et al. Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase
Chamberlain et al. The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
WO1999004008A3 (en) Cloned genomes of infectious hepatitis c viruses and uses thereof
DE69631375D1 (en) METHOD FOR IN VITRO REPRODUCTION OF RNA-DEPENDENT RNA POLYMERASE AND TERMINAL NUCLEOTIDYL TRANSFERASE ACTIVITY OF HEPATITIS C VIRUS (HCV)
MX9700817A (en) Vr-2332 viral nucleotide sequence and methods of use.
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2006133911A3 (en) Hepatitis c virus nucleic acid vaccine
HUP0203305A2 (en) Infectious clones
AU2003284689A8 (en) Nucleic acid construct containing hepatitis c virus (hcv) of genocype 2a genome-origin nucleic acid and cell having the nucleic acid construct transferred thereinto
Butkiewicz et al. Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
EP1840214A4 (en) Attenuated chimeric flavivirus bearing attenuated japanese encephalitis virus gene as backbone
WO2003031934A3 (en) Identification of oligonucleotides for the capture, detection and quantitation of hepatitis b viral dna
AU5322800A (en) Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof
Gwack et al. RNA-stimulated ATPase and RNA helicase activities and RNA binding domain of hepatitis G virus nonstructural protein 3
Kimbi et al. The effect of the G1888A mutation of subgenotype A1 of hepatitis B virus on the translation of the core protein
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
CY1110238T1 (en) Vaccine of the Virus C
AU8156594A (en) Non-A non-B sequences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2461380

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002773740

Country of ref document: EP

Ref document number: 2002337840

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10492178

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 740/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003534559

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20028246659

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002773740

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002337840

Country of ref document: AU